Previous results using subcutaneous immunization with MVA-BN-HER2 against CT26.HER2 tumors indeed showed a slight increase of Lag3-positive cells in the tumor microenvironment 16 days after vaccination48. This evidence concerns the gene ERBB2 and neoplasm.